

# Instructions for Authors

## *Neurotherapeutics*<sup>®</sup>

*Neurotherapeutics*<sup>®</sup> is the official journal of the American Society for Experimental NeuroTherapeutics (ASENT). The journal publishes original research articles and invited topical reviews related to the treatment of neurological disorders in addition to invited current perspectives, occasional commentaries and invited meeting abstracts. *Neurotherapeutics*<sup>®</sup> appears quarterly in print and online. All articles are posted online in advance of print after copyediting and approval of Author Proofs. The target audience includes researchers and practitioners in the field of neurotherapeutics including neurologists, neurosurgeons, psychiatrists, and pain specialists, as well as basic scientists, and individuals from academia, advocacy, government, and industry.

### **Editorial Policy**

Submission of a manuscript implies that the work described has not been published previously, except in the form of an abstract or briefly in a review article; that it is not under consideration for publication in another journal; and that its publication has been approved by all co-authors, if any, as well as by the responsible authorities – tacitly or explicitly – at the institution where the work has been carried out. At the time of submission, a Conflict of Interest form for EACH co-author is required and must be uploaded. This form is available on the website (<http://www.editorialmanager.com/nerx/>).

Authors are responsible for obtaining approval to republish copyrighted material. The publisher does not defray any associated costs and will not be held legally responsible should there be any claims for compensation due to copyright infringement or plagiarism.

### **Invited Reviews for Thematic Special Issues**

Each quarterly issue of the journal includes a series of invited review articles relating to a specific topical theme. The selection of manuscripts is made by one or more designated guest editors, who also organize the peer review. Manuscripts for invited reviews should be uploaded according to the online submission instructions given below, and also found on the submission website:

<http://www.editorialmanager.com/nerx/>

Because *Neurotherapeutics*<sup>®</sup> volumes are topic specific and are published according to a strict schedule, it is very important that authors adhere to the deadlines as communicated by the *Neurotherapeutics*<sup>®</sup> Editorial Office or designated guest editor(s). **Articles submitted late cannot be rolled over to the next issue as topics do not carry forward.**

### **Original Articles**

Original research articles may be submitted for consideration at any time and must be uploaded through the submission website (<http://www.editorialmanager.com/nerx/>).

### **Current Perspectives**

Current Perspectives are invited articles about current hot topics in the neurotherapeutics field. These provide a critical analysis of the topic being covered, our understanding of pathogenetic mechanisms of neuropsychiatric conditions, new treatment modalities, or their impact on clinical care.

## Commentaries

These are invited opinion pieces about original articles published in *Neurotherapeutics*<sup>®</sup> written by experts in their fields providing an analysis of the research and its findings.

## Review Process

Original Research articles are initially reviewed in-house prior to a decision being made as to whether an article will be sent out for additional peer review. Editorial decisions are generally made about possible peer review within a few days.

With each submission of all article types, authors should provide the name and contact information, including email addresses, of four possible reviewers who are familiar with the subject area and who have the expertise to critically evaluate the submission. The Editorial Office and Guest Editors of a special issue may make use of the authors' suggested reviewers or may make their own assignments.

**THERE ARE NO PAGE CHARGES, NOR CHARGES FOR COLOR FIGURES WHEN PUBLISHING IN *Neurotherapeutics*<sup>®</sup>**

## Preparation of Manuscripts

### Organization of Submitted Manuscripts

Manuscript files must contain a title page, summary, corresponding author information, section headings where appropriate, Acknowledgments, References, Table and Figure Legends, in addition to separate artwork files for figures (see instructions for artwork detailed below).

Invited review articles should generally fall in the range of 20-25 pages for full review articles, 6 pages for guest editors' editorials, 6-8 pages for Current Perspectives, and 4-5 pages for Commentaries, all with double line spacing in a single word processing document (MS Word). **Figures, references, acknowledgments, etc. are additional pages.**

### Title Page

The title page must include:

- The name(s) of all authors (first name, middle initial, surname)
- A concise and informative title
- The affiliation(s) and address(es) of the author(s) and their institutions, departments or organizations (use the following symbols in this order: \*, †, ‡, §, ¶, ||, #, \*\*, ††, ‡‡, §§, ¶¶, || ||, ##).
- Article type (invited review or original research); if invited review, state issue theme
- The e-mail address, telephone and fax numbers of the corresponding author
- A running title (not to exceed 40 characters)

### Summary

A summary of 150 to 250 words must be provided. The summary should be unstructured and should not contain any undefined abbreviations. References should not be included in the summary.

### Key Words

Authors must provide 5 or 6 Key Words that can be used for indexing purposes.

## Text

### Manuscript Format

- Manuscripts should be submitted in Microsoft Word (.docx) or RTF (.rtf) file format.
- All text should be double-spaced (including references, tables, and legends).
- For original articles, subheadings of Introduction, Methods, Results, and Discussion should be used.
- Margins should be 1 inch wide.
- Use the automatic page numbering function to number the pages.
- Use a traditional serif or sans serif font for text, at least 11.5 point. Times New Roman and Arial are acceptable.
- The following sections should begin on separate pages: title page, summary/key words, references, acknowledgments, each table, and figure legend.
- Major heading and up to two levels of subheadings are permitted. Headings are set in bold type. If there are any subheadings of the article, the level of heading (major, minor, subminor) should be clear from the formatting.
- Use italics for emphasis; do not underline.
- Do not use field codes.
- Use tab stops or other commands for indents; do not use multiple spaces to indent.
- Use the table function to make tables; do not embed spreadsheets.
- Use the equation editor or MathType for equations. (Note: If you use Word 2007, do not create the equations with the default equation editor but use the Microsoft equation editor or MathType instead. Manuscripts with mathematical content can also be submitted in LaTeX.)

### Abbreviations

Abbreviations should be defined at first mention and used consistently thereafter. Abbreviations should not be used only once unless it seems necessary for clarity.

### Acknowledgments

Acknowledgments of people, grants, funding sources, etc., should be placed in a separate section before the reference list. The names of funding organizations should be included in this section and written in full.

## References

### Citation

Reference citations in the text should be identified in numerical order in the text using Arabic numbers within brackets.

*Some examples:*

- Negotiation research spans many disciplines [1].
- This result was later contradicted by Becker and Seligman [2].
- This effect has been widely studied [1-3].

### Reference list

The list of references should only include works that are cited in the text and that have been published or accepted for publication. Personal communications and unpublished works should only be mentioned in the text and permission for their use must be obtained. **Do not use footnotes or endnotes as a substitute for a reference list.**

Entries in the reference list should be double-spaced and numbered consecutively in the order of first citation within the text.

**References should follow the Vancouver style format.** Articles that have been accepted for publication but not yet published should be listed as “in press”.

*Neurotherapeutics*<sup>®</sup> reference format:

- If there are more than six authors, the bibliography should list only three authors followed by *et al.*
- Journal name is **not** underscored or italicized, and should be followed immediately by publication year, volume number, colon, page numbers (see example below).
- Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word Abbreviations, see <http://www.issn.org/2-22661-LTWA-online.php>
- References are numbered in the order of citation in the text and should appear in the text as Arabic numbers in brackets
- When the authors name is referred to in the text, the citation should be closely positioned to the author’s name. Thus avoid “Smith et al. found that . . . [47]” and instead use “Smith et al. [47] found that...”.
- The reference list must be double-spaced, as is the body of the manuscript.
- Ensure that references are listed in order of presentation in the text and that all references are cited.
- Do not provide issue number of a journal article

Examples:

***Journal article***

Krupp LB, Elkins LE. Fatigue and declines in cognitive functioning in multiple sclerosis. *Neurology* 2000;55:934-939.

***Published abstract***

van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJB, Eskens FALM, Delattre J-Y. Temozolomide chemotherapy in recurrent oligodendroglioma. *Neurology* 2000;54 (suppl 3):A12. Abstract.

***Unpublished material***

Mark MH, Dickson DW, Schwarz KO, et al. Familial diffuse Lewy body disease. Presented at the 10th International Symposium on Parkinson's Disease; October 19, 1991; Tokyo.

***Letter***

Neurology Assessment Panel. Assessment of neuropsychological testing. *Neurology* 1997;49:1183-1185. Letter.

***Online book or website***

Garrow A, Weinhouse G. Anoxic brain injury: assessment and prognosis. In: UpToDate Cardiovascular Medicine [online]. Available at: [www.UpToDateInc.com/card](http://www.UpToDateInc.com/card). Accessed February 22, 2006.

***Online journal article***

Miyamoto O, Auer RN. Hypoxia, hyperoxia, ischemia, and brain necrosis. *Neurology* [serial online] 2000;54:362-371. Available at: [www.neurology.org](http://www.neurology.org). Accessed February 23, 2006.

### ***Monograph in electronic format***

Chee M, Chiappa K. Waveguide: an EEG atlas on CD-ROM. Philadelphia: Lippincott Williams & Wilkins, 1998.

### ***Computer file***

EMG analyzer software [computer program]. Version 1.0. Tustin, CA: B & L Engineering, 1998.

### ***Online Correspondence***

Henderson VW, Drachman DA. Dementia and voter competence [electronic response to Swerdloff, Post-election anecdote]. *Neurology* 2002. <http://www.neurology.org/cgi/eletters/58/7/995> (accessed 21 May 2002).

### **Cross-citation**

For invited reviews only it may be appropriate to cite one or more of the other articles in the dedicated volume. This will produce flow among the articles and cohesiveness to the volume. When another paper in the issue is cited the author should include the source in the numbered reference list and provide as much detail of the title and authors of the paper as is known, so that the Production Editor can complete the actual page range when the issue is compiled. To facilitate cross-citation, the guest editors will provide a table of contents to authors a few weeks before the due date of the manuscript.

### **Tables**

- All tables are to be numbered using Arabic numerals (example: Table 2).
- Tables should always be cited in text in consecutive numerical order.
- For each table, please supply a title. Most figures will also have a caption (situated below the table body) that explains the components of the table.
- Identify any previously published material by giving the original source in the form of a reference at the end of the title.
- Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance values and other statistical data) and included in the caption.

### **Artwork**

- Color art is free of charge for online publication and in print.
- Authors must submit all artwork electronically.
- Indicate which graphics program was used to create the artwork.
- For vector graphics, the preferred format is EPS or PDF; for bitmaps or halftones, please use TIFF or PNG format. PDF or Microsoft Office files are also acceptable as long as they are of sufficient resolution.
- Vector graphics containing fonts must have the fonts embedded in the files.
- Name your figure files with "Fig" and the figure number, e.g., Fig1.eps.
- Multipart figures to be assembled by the publisher must be clearly identifiable by the file names: fig1A.tif, fig1B.tif, Fig1C.tif, etc. The physical labels (A, B, C, etc.) will be added by the publisher.
- Resolution should be 300 dpi for images and 1200 dpi for line art.
- For optimal results, scaling, rotation, and cropping should be done using an image editing program (such as Adobe Photoshop) rather than a page layout program. All images must be easily readable and have good contrast. To ensure clarity fonts and type size should be uniform among the parts of a multipart figure, and among all of the figures within a manuscript.
- Titles and legends should not appear within the figure file, but should be provided in the list of captions included in the manuscript.

### **Line Art**

- Definition: Black and white graphic with no shading. The best way to produce line art is in vector format (for example, with Adobe Illustrator). Vector art should be saved as an .eps or as a separate .pdf file. (Do not use .pdf files to transmit manuscript text!) Line art can also be produced as a bitmap with a minimum resolution of 1200 dpi and saved in .tif or .png format.
- Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at final size.
- All lines should be at least 0.1 mm (0.3 pt) wide.
- Vector graphics containing fonts must have the fonts embedded in the files, unless the fonts are standard such as Ariel or Helvetica.

### **Halftone Art**

- Definition: Photographs, drawings, or paintings with fine shading, etc.
- If any magnification is used in the photographs, indicate this by using scale bars within the figures themselves.
- Halftones should have a minimum resolution of 300 dpi.

### **Combination Art**

- Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive lettering, color diagrams, etc.
- Combination artwork should have a minimum resolution of 600 dpi.

### **Color Art**

- Color art is free of charge. Color illustrations should be submitted as RGB (8 bits per channel).

### **Lettering Within Figures**

- It is best to use a sans serif font such as Arial or Helvetica for lettering.
- Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm high (8–12 pt).
- Variance of type size within an illustration should be minimal; e.g., do not use 8-pt type on an axis and 20-pt type for the axis label.
- Avoid effects such as shading, outline letters, etc.

### **Figure Numbering**

- All figures are to be numbered using Arabic numerals. Do not include the numbers within the artwork itself.
- Figures should always be cited in the text in consecutive numerical order.
- Figure parts should be denoted by lowercase letters (a, b, c, etc.).

### **Figure Captions**

- Each figure should have a concise caption describing accurately what the figure depicts. Include the captions in the text file of the manuscript as a figure legend, not in the artwork figure file.
- Figure captions begin with the term “**Fig.**” in bold type, followed by the figure number, also in bold type (Arabic numerals).
- No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the caption.
- Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate points in graphs.
- Identify previously published material by giving the original source in the form of a reference citation at the end of the figure caption (see “Permissions” section below).

### **Figure Placement and Size**

- When preparing your figures, it is best to size figures to fit in the width of 1 column. If the figure cannot be sized to a single column, it is acceptable to size to 1.5 or the full 2 column width.
- Each figure should be sized (column width and depth) to one of the following as desired for printing:
  - 1 column: 19 picas (approx. 3 1/8 inches or 7.94 cm) wide
  - 1.5 columns: 28.5 picas (4 3/4 inches or 12.07 cm) wide
  - 2 columns: 40 picas (6 5/8 inches or 16.83 cm) wide

### **Permissions**

If you include figures that have already been published elsewhere, you must obtain permission from the copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant electronic rights at no charge (free) and that Springer is unable to refund any costs that may have incurred to receive these permissions. In such cases, material from other sources should be used.

### **Accessibility**

In order to give people of all abilities and disabilities access to the content of your figures, please make sure that:

- All figures have descriptive captions (so that blind users can use text-to-speech software or a text-to-Braille hardware)
- Patterns are used instead or in addition to colors for conveying information (so that color-blind users are able to distinguish the visual elements)

**Conflict of Interest.** All authors must submit Conflict of Interest forms at the time of submission, or the submission will be returned to the uploading/corresponding author – delaying the review process. When authors submit a manuscript they are responsible for disclosing all financial and personal relationships that might bias their work (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements). The forms are available on the site as fillable PDFs, and should be uploaded at the time of manuscript submission.

The journal abides by the Uniform Requirements for Manuscripts Submitted to Biomedical Journals of the International Committee of Medical Journal Editors. Information is available at:  
<http://www.icmje.org/>

Published articles will include information on conflicts of interest (linking to forms submitted).

Other disclosures are included in the manuscript in the Acknowledgments section. Authors should identify individuals who provide research reagents or writing assistance and disclose the funding source for this assistance. Investigators must disclose potential conflicts to study participants and should state in the Methods section of the manuscript whether they have done so.

Reviewers or editorial staff having potential conflict of interest will be required to disclose conflict of interest and/or remove themselves from review of manuscript.

**Protection of Human Subjects Research.** When reporting experiments with human subjects, authors should indicate whether the procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (World Medical Association Declaration of Helsinki

2000). If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach, and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. The institutional review board should be identified in the Methods section or other appropriate section.

**Human Subjects Informed Consent.** Studies with human subjects are required to state in the manuscript that all subjects gave their consent to the study in accordance with the informed consent regulations of the institution where the research was conducted.

**Protection of Animals in Research.** When reporting experiments using animals, authors should indicate whether the institutional and national guide for the care and use of laboratory animals was followed. The institutional Animal Care and Use Committee should be identified in the Methods section or other appropriate section.

## **Online Manuscript Submission**

Authors must submit their manuscripts using the journal's online submission system. Electronic submission substantially reduces the editorial processing and reviewing times and shortens overall publication times. Our online manuscript submission and review system offers authors the option to track the progress of the review process of manuscripts in real time. Please follow the hyperlink "Submit online" on the right and upload all of your manuscript files following the instructions given on the screen.

<http://www.editorialmanager.com/nex/>

Should you encounter any difficulties while submitting your manuscript, please contact the Publishing Editor via the "Contacts" link at the right of the journal homepage.

## **Accepted Submissions**

Upon acceptance of your article you will receive a link to the special Author Query Application at Springer's web page where you can sign the Copyright Transfer Statement online and indicate whether you wish to order and pay for Open Choice and/or offprints. Open Choice includes a charge to the Corresponding Author (currently USD \$3000). Once the Author Query Application has been completed, your article will be processed and you will receive the Proofs for approval.

## **Open Choice**

In addition to the normal publication process (whereby an article is submitted to the journal and access to that article is granted to customers who have purchased a subscription), Springer now provides an alternative publishing option: Springer Open Choice. A Springer Open Choice article receives all the benefits of a regular subscription-based article, but in addition is made available publicly through Springer's online platform SpringerLink. We regret that Springer Open Choice cannot be ordered post facto for published articles.

**The current charge for Open Choice is USD \$3000. For additional information, please see:**

<https://www.springer.com/gp/open-access/springer-open-choice>



## Copyright Transfer

Authors will be asked to transfer copyright of the article to the Publisher (or grant the Publisher exclusive publication and dissemination rights). This will ensure the widest possible protection and dissemination of information under copyright laws. Articles where authors opt to pay for Open Choice do not require transfer of copyright as the copyright remains with the author. In opting for Open Choice, authors agree to the Springer Open Choice License.

## Author Proofs and Proofreading

Proofs will be sent by Springer's typesetting production group and emailed to the corresponding author for approval. The purpose of the proof is to review copyediting, check for typesetting errors and the completeness and accuracy of the text, tables and figures. Substantial changes in content, e.g., new results, corrected values, title and authorship, are not allowed without the approval of the Editor. **Once proofs are approved by the corresponding author and the paper is published online, further changes can only be made in the form of an Erratum, which will be hyperlinked to the article. We encourage the corresponding author to review the Author Proofs with great care in order to avoid unnecessary Erratum. An author may request a Second Set of Proofs for approval to ensure accuracy in all corrections.**

## Online First

The article will be published online after receipt of the corrected proofs. This is the official first publication citable with the DOI. After release of the printed version, the paper can also be cited by issue and page numbers.

## PubMed Central

All articles in *Neurotherapeutics* are automatically deposited upon issue publication in PubMed Central with a 12-month embargo on public access.

\* \* \*



<http://www.springer.com/journal/13311>

Neurotherapeutics

The Journal of the American Society for Experimental  
NeuroTherapeutics

Editor-in-Chief: Mouradian, M.

ISSN: 1933-7213 (print version)

ISSN: 1878-7479 (electronic version)

Journal no. 13311